QTR Family Wealth LLC Buys 1,911 Shares of Bristol Myers Squibb Company $BMY

QTR Family Wealth LLC increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 28.8% in the second quarter, Holdings Channel.com reports. The institutional investor owned 8,541 shares of the biopharmaceutical company’s stock after acquiring an additional 1,911 shares during the period. QTR Family Wealth LLC’s holdings in Bristol Myers Squibb were worth $395,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC increased its stake in shares of Bristol Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares in the last quarter. Baker Tilly Wealth Management LLC increased its stake in shares of Bristol Myers Squibb by 15.1% during the first quarter. Baker Tilly Wealth Management LLC now owns 6,956 shares of the biopharmaceutical company’s stock valued at $424,000 after purchasing an additional 911 shares in the last quarter. NBC Securities Inc. increased its stake in shares of Bristol Myers Squibb by 102,110.0% during the first quarter. NBC Securities Inc. now owns 10,221 shares of the biopharmaceutical company’s stock valued at $623,000 after purchasing an additional 10,211 shares in the last quarter. Fragasso Financial Advisors Inc bought a new position in shares of Bristol Myers Squibb during the first quarter valued at approximately $208,000. Finally, Merit Financial Group LLC increased its stake in shares of Bristol Myers Squibb by 21.6% during the first quarter. Merit Financial Group LLC now owns 51,601 shares of the biopharmaceutical company’s stock valued at $3,147,000 after purchasing an additional 9,166 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Daiwa America downgraded shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price target on the stock. in a report on Tuesday, August 5th. Wall Street Zen cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. Finally, Citigroup cut their price target on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Hold” and a consensus target price of $56.38.

Insider Buying and Selling at Bristol Myers Squibb

In other news, EVP David V. Elkins sold 56,000 shares of Bristol Myers Squibb stock in a transaction on Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares in the company, valued at $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.07% of the stock is owned by corporate insiders.

Bristol Myers Squibb Trading Up 1.9%

Shares of BMY stock opened at $45.00 on Wednesday. Bristol Myers Squibb Company has a 12-month low of $42.96 and a 12-month high of $63.33. The company has a current ratio of 1.21, a quick ratio of 1.11 and a debt-to-equity ratio of 2.54. The firm’s 50 day moving average is $46.52 and its 200 day moving average is $48.86. The stock has a market capitalization of $91.59 billion, a P/E ratio of 18.15, a P/E/G ratio of 2.26 and a beta of 0.35.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.07 by $0.39. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The company had revenue of $12.27 billion for the quarter, compared to analysts’ expectations of $11.32 billion. During the same quarter last year, the company posted $2.07 earnings per share. The firm’s quarterly revenue was up .6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. Research analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be issued a $0.62 dividend. The ex-dividend date is Friday, October 3rd. This represents a $2.48 annualized dividend and a yield of 5.5%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 100.00%.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.